Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of Schizophrenia, for monitoring the effectiveness of Schizophrenia treatment, identifying patients most likely to respond to a particular therapeutic treatment and for drug development. European Patents via NewsEdge Corporation : Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of Schizophrenia, for monitoring the effectiveness of Schizophrenia treatment, identifying patients most likely to respond to a particular therapeutic treatment and for drug development. Schizophrenia-Associated Features (SFs), detectable by two- dimensional electrophoresis of cerebrospinal fluid, serum or plasma are described. The invention further provides Schizophrenia-Associated Protein Isoforms (SPIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising isolated SPIs, antibodies immunospecific for SPIs, and kits comprising the aforesaid. Pub. No.: EP 1259607 Appl. Data: EP 01909957 2001 02 23 If you would like to purchase a copy of this patent, please call MicroPatent at 800-648-6787. Applicant: Oxford GlycoSciences (UK) Limited << Copyright ©2002 MicroPatent >>
VII Российский конгресс с международным участием «Молекулярные основы клинической медицины – возможное и реальное» пройдет в Санкт-Петербурге 16 декабря, 2024
Ведущий научный сотрудник НЦПЗ Ирина Федоровна Рощина награждена медалью Г.И. Челпанова 10 декабря, 2024
